You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
JPM just published a special issue on "Untold Stories about Personalized Medicine: If You Thought Personalized Medicine Is for Others to Worry about, Think Again".
There are eight high quality papers, including one review article and case report and six research articles published online; four more articles are being processed and will soon be published.
The guest editor, Dr. Felix W. Frueh from the University of North Carolina said: "This special issue of the Journal of Personalized Medicine looks into the future and asks several stakeholders, some obvious and some less obvious, how they view personalized medicine influencing, or being influenced by, their area of interest."
